
On Friday, Genmab's partner Janssen Pharmaceuticals has been granted approval to launch lung cancer drug Rybrevant from the US Food and Drug Administration (FDA).
The drug was developed via Genmab's Duobody platform making it the first product from this platform to receive regulatory approval.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app